The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.
"From our perspective, we use those data to generate quantitative tools and solutions, where the clinicians can get a better understanding of how these models convey information with regard to a particular biomarker or end point.”
The Critical Path for Alzheimer’s Disease (CPAD) is a public-private partnership aimed at creating new tools and methods that can be applied to increase the efficiency of drug development in neurodegenerative diseases that progress to dementia with the shared characteristics of Alzheimer disease (AD). In August 2018, CPAD celebrated its tenth anniversary of the original formulation of the of the Coalition Against Major Diseases (CAMD)—the founding consortium.
At the 2021 Alzheimer’s Association International Conference, July 26-30, members including Sudhir Sivakumaran, PhD, and Klaus Romero, MD, MS, FCP, shared an update on CPAD’s database and reemphasized the primary objective of the consortium. As of October 2020, CPAD’s database contained 41 studies, standardized to the AD Clinical Data Interchange Standards Consortium (CDISC) standards, of which 3 datasets were used to generate analysis subsets. Serving as a neutral third party, CPAD provides a safe harbor for individual organizations to share data in a pre-competitive environment.
Sivakumaran, vice president, Neuroscience Program, and Executive Director, CPAD, and Romero, chief science officer, CPAD, sat down with NeurologyLive to discuss the advantages this consortium brings to clinicians within the AD community and why the trough of data will lead to greater clinical trial success.